ProCE Banner Activity

Noncovalent BTK Inhibitors in Mantle Cell Lymphoma: What You Should Know

Clinical Thought

Read this expert commentary on the latest information about the emerging role of reversible noncovalent BTK inhibitors in the management of relapsed/refractory MCL.

Released: October 20, 2022

Expiration: October 19, 2023

Share

Faculty

Julie M. Vose

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.